Orexigen Therapeutics

{{Infobox company

| name = Orexigen Therapeutics, Inc.

| logo = File:Logo_of_Orexigen_Therapeutics.jpg|

| logo_size =

| logo_alt =

| logo_caption =

| logo_padding =

| image =

| image_size =

| image_alt =

| image_caption =

| native_name =

| native_name_lang =

| former_name =

| type = Public

| traded_as = {{NASDAQ|OREX}}

| industry =

| founded = {{start date and age|2002}}

| founder = Eckard Weber

| hq_location = La Jolla, California, U.S.

| hq_location_city =

| hq_location_country =

| area_served =

| key_people =

| products =

| brands =

| services =

| owner =

| homepage = {{url|orexigen.com}}

}}

Orexigen Therapeutics, Inc. is a public American pharmaceutical company focused on development of treatments for obesity. The company is based in La Jolla, California and was established by Eckard Weber in 2002. As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX.

The company has a single product, Contrave, approved for use in the United States in 2014. Contrave was designed not only to curb hunger but also reduce cravings. Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.{{Unreliable source?|date=June 2015}}

Orexigen declared bankruptcy in 2018 and was sold to Nalpropion.

References

{{reflist|refs=

{{cite news | author=Osborne, Spencer | title=Orexigen On A Tear - In The Wrong Direction | date=7 October 2014 | work=Seeking Alpha | url=https://seekingalpha.com/article/2544335-orexigen-on-a-tear-in-the-wrong-direction }}

{{cite web |title=OREX Key Statistics |url=http://www.marketwatch.com/investing/stock/orex/profile |archive-url=https://web.archive.org/web/20091124093857/http://www.marketwatch.com/investing/stock/OREX/profile |url-status=dead |archive-date=November 24, 2009 |accessdate=12 September 2014 |website=MarketWatch }}

{{Cite web|title=Orexigen Enters into Agreement to Sell Company to Newly Formed Entity Nalpropion Pharmaceuticals|url=https://www.biospace.com/article/orexigen-enters-into-agreement-to-sell-company-to-newly-formed-entity-nalpropion-pharmaceuticals/|access-date=2020-06-15|website=BioSpace|language=en-US}}

{{Cite news|url=https://www.reuters.com/article/us-orexigen-bankruptcy-idUSKCN1GO0GU|title=U.S. drugmaker Orexigen files for Chapter 11 bankruptcy|date=2018-03-12|work=Reuters|access-date=2019-07-30|language=en}}

{{Cite web|title=No magic pill for obesity: Orexigen files for bankruptcy|url=https://www.biopharmadive.com/news/orexigen-bankruptcy-asset-contrave-obesity/518914/|access-date=2020-06-15|website=BioPharma Dive|language=en-US}}

}}

Category:Health care companies based in California

Category:Pharmaceutical companies established in 2002

Category:Pharmaceutical companies of the United States

Category:Companies listed on the Nasdaq

Category:2002 establishments in California